View all CSAC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit

Acknowledgement of Commercial Support

This activity is supported by educational grants from Lilly and Merck.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.


Cancer Summaries and Commentaries™: Update From Chicago: Advances in the Treatment and Management of Breast Cancer PER Pulse™ Recap

PER Pulse Recap

PER Pulse™ Recap


Cancer Summaries and Commentaries™: Update From Chicago: Advances in the Treatment and Management of Breast Cancer is an online CME publication designed to update physicians on key clinical data and highlights in breast cancer presented at a major 2017 oncology annual meeting held in Chicago. It is accompanied by audio commentaries from Ricardo Alvarez, MD, and Sara Hurvitz, MD, who offer their perspectives on the data and, when appropriate, how clinicians can integrate these findings into practice to improve patient care.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on results from the phase III MONARCH 2 trial, an ongoing study evaluating the efficacy of the CDK4/6 inhibitor abemaciclib plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who have experienced disease progression after endocrine therapy. During their interviews, Drs. Alvarez and Hurvitz discussed:

  • Their opinions on the clinical significance of the MONARCH 2 results: abemaciclib improved progression-free survival by just over 7 months when added to fulvestrant after 1 line of endocrine therapy.
  • The notable differences in the toxicity profiles of abemaciclib, palbociclib, and ribociclib. Whereas abemaciclib is associated with a lower incidence of grade 3 and 4 neutropenia versus palbociclib and ribociclib, the rates of gastrointestinal toxicity (most notably, diarrhea) are higher with abemaciclib. Additionally, the potential for QT interval prolongation is higher with ribociclib versus the other agents.
  • Factors to consider when selecting a CDK4/6 inhibitor, including their comparative safety profiles, pre-existing comorbidities, and patient preference regarding potential adverse effects and their implications for monitoring (eg, blood count testing, electrocardiogram) and dose schedule.

2 of 3
PER Pulse™ Recap

Cancer Summaries and Commentaries™: Update From Chicago: Advances in the Treatment and Management of Breast Cancer is an online CME publication designed to update physicians on key clinical data and highlights in breast cancer presented at a major 2017 oncology annual meeting held in Chicago. This is accompanied by audio commentaries from Ricardo Alvarez, MD, and Sara Hurvitz, MD who offer their perspectives on the data and, when appropriate, how clinicians can integrate these findings into practice to improve patient care.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on results from cohort A of the phase II KEYNOTE-086 trial of pembrolizumab for patients with previously treated metastatic triple-negative breast cancer (TNBC), regardless of PD-L1 expression. In this online activity, the faculty discuss the study results in the context of current and emerging strategies for patients with disease progression after receiving 1 or more lines of therapy for metastatic TNBC.

During their interviews, Drs. Alvarez and Hurvitz discussed:

  • The rationale for, and design of, the KEYNOTE-086 trial, as well as key findings related to cohorts A and B.
  • Their reactions to the cohort A and B data. They noted that it is important to keep in mind that patients in cohort A were heavily pretreated and had a heavy disease burden.
  • The small number of patients with a durable response observed in this trial and the importance of conducting future studies to identify predictive markers.
  • Outcomes based on tumor expression of PD-L1. Survival endpoints were similar regardless of PD-L1 expression.
  • The results of KEYNOTE-086 in the context of previously reported data from studies of checkpoint inhibition for breast cancer.
  • Ongoing investigations of pembrolizumab and other checkpoint inhibitors for breast cancer, including their perspectives on relevant data from the iSPY trial presented in Chicago.

3 of 3
PER Pulse™ Recap

Cancer Summaries and Commentaries™: Update From Chicago 2017: Advances in the Treatment and Management of Breast Cancer is an online CME publication designed to update physicians on key clinical data and highlights in breast cancer presented at a major 2017 oncology annual meeting held in Chicago. This is accompanied by audio commentaries from Ricardo Alvarez, MD, and Sara Hurvitz, MD, who offer their perspectives on the data and, when appropriate, how clinicians can integrate these findings into practice to improve patient care.

This third of 3 PER Pulse™ Recaps summarizing the program focuses on results from the phase III OlympiAD trial that compared the efficacy and safety of olaparib versus standard chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation. During their interviews, Drs. Alvarez and Hurvitz discussed:

  • That an approximately 3-month improvement in progression-free survival was observed with olaparib versus chemotherapy in a population that was heavily pretreated for metastatic germline BRCA-mutated breast cancer (approximately half with triple-negative breast cancer).
  • The promise of these positive data that represent the first phase III clinical trial data in metastatic germline BRCA-mutated breast cancer.
  • The encouraging safety profile of olaparib. The rate of grade 3 or higher adverse effects was 36.6% with olaparib versus 50.5% with chemotherapy. Dr. Hurvitz commented that, overall, it was tolerated quite well and would offer patients a nonchemotherapeutic option if approved.
  • Whether combining a PARP inhibitor with low-dose chemotherapy or an inhibitor of another pathway would augment the positive outcomes observed this study.




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By